Francesca Zacchi
@FrancescaZacc14
Followers
36
Following
22
Media
5
Statuses
28
MD, Oncologist PhD student at University of Verona
Verona, Veneto
Joined July 2022
🚨 Published our #Review on Senescence in Prostate Cancer! Honored to be part of this collaboration with outstanding colleagues! @quimmateo @julianbrandariz @luisa_bacc76421 @DavidP_Labbe AndreaZivi #Oncology #CancerResearch #Senescence #ProstateCancer
1
2
4
🚨 Just published our #MetaAnalysis: Interleukin-8 as a prognostic biomarker in #RenalCellCarcinoma 👉 https://t.co/QsEUhSRb4u Grateful to @saramerler, all co-authors, and especially Michele Milella, Head of Oncology, Verona. #Oncology #CancerResearch #Biomarkers #RCC
academic.oup.com
AbstractBackground and Objective. Interleukin-8 (IL-8) is a chemokine involved in inflammation and primary immune response, playing a key role in recruitin
0
0
0
🔬Call for Papers! 🧬 We are excited to announce that our Frontiers in Oncology (Genitourinary Oncology) Research Topic "Histological and Molecular Subtypes of Prostate Cancer: Biology, Biomarkers, and Therapeutic Implications" is now open for submissions! https://t.co/JM26EENUl3
frontiersin.org
Prostate cancer is one of the most common cancers in men and a leading cause of cancer-related death in its metastatic form. While early-stage prostate cance...
0
0
0
European Urology Oncology (online 28 April 2025). "Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study".
0
0
0
🎉I am excited to share our latest publication in Frontiers in Oncology, AvePem Study, a real word study that compare 1L maintainance Avelumab vs 2L Pembrolizumab https://t.co/KeslBqgzzD
frontiersin.org
Introduction and objectivesPatients (pts) with metastatic urothelial carcinoma (mUC) gain substantial benefit from immunotherapy exposure. If they do not exp...
0
0
1
Our latest paper is out in @CellRepMed - Functional RAD51-IF to detect HRR defects in #ProstateCancer - exploring correlations between HRR mutations, HRD scores, and RAD51-IF in mPC biopsies #OpenAccess #CancerResearch
https://t.co/YhqnKVvdps
0
17
69
Our review on the current state of PARPi development for #prostatecancer is now out in @EurUrolOncol - led by @FrancescaZacc14 + help from several experts in the field https://t.co/L0DTvg46CZ
2
19
54
🎙️ CALL FOR PAPERS on SPECIAL RESEARCH TOPIC in FRONTIERS IN ONCOLOGY 🧬 Research Topic: Prostate Cancer Senescence: Therapeutic Challenges and Opportunities. Manuscript Summary Submission Deadline 28Feb2025 Manuscript Submission Deadline 30June2025 Link: https://t.co/HbnEeFeKCM
0
0
0
Excited to share our publication in European Urology Oncology. It has been an honor to collaborate with leading experts in prostate cancer, and I am incredibly grateful for the exceptional mentorship from Dr. Joaquin Mateo. Full article: https://t.co/6PXTfqmM7b
0
0
1
Excited to share the findings from the multicenter real-world ARON-3 study, now published in European Urology Oncology! 📌 The analysis highlights that apalutamide in mHSPC remains a safe and effective treatment in real-world practice. 📖 Full article: https://t.co/BHSXkZza7a
0
0
2
📢 #mHNPC, a distinct biological entity? Read our last #review!!! Thanks to @quimmateo and @ArkaitzLab
https://t.co/uTnQKjAVAx
0
1
3
A joint effort with @quimmateo, highlighting the clinical relevance, emerging molecular distinctive features and therapeutic progress in the most aggresive clinical manifestation of prostate cancer. @ContraCancerEs @CIBERONC
@ASEICAnews
https://t.co/WDz5kC2rZe
1
8
17
@myESMO Recommendations for clinical reporting of genomics - now published in @Annals_Oncology. We're aiming to advance rational, evidence-based use of genomics in patient care and harmonize biomarker interpretation in cancer treatment https://t.co/GohY3dWkQB
1
10
31
Amazing experience in #ASCO24 at the Poster Session-GU Cancer. We presented our work evaluating the HRR status in mPC by NGS and the functional RAD51-IF assay.🧬💻🔬 Abstract 5024 Prostate Cancer Translational Research Team 🔝🚀 @VHIO @vallhebron @quimmateo Thank you to all!!
0
2
17
3
5
13
Identifican nuevos biomarcadores de imagen para predecir la respuesta al tratamiento en pacientes con cáncer de próstata con metástasis óseas 🗞️ Los resultados del estudio #iPROMET se han publicado en @EUplatinum ➡️ https://t.co/6kVAhEpacg
0
3
7
Our latest paper is now out in @EUplatinum -A prospective study of whole-body MRI in mCRPC with bone mets: the IPROMET clinical trial. Work with @RaqPerezLopez @radiomicsVHIO
https://t.co/Dg3UjSGvdO
3
15
55
Next Wednesday @PCF_Science is organising a webinar about current use and future prospects for PARPi in #prostatecancer - looking forward to this discussion! If you want to join, the link is below
Join us for the PCF DNA repair working group's panel discussion on "Emerging Trends in PARP Targeting Therapies". Feel free to send us your questions that you want us to discuss (ndesarkar@mcw.edu). #pcf #prostatecancer #parpi @PCF_Science
0
5
18